Preclinical Data for Alzheimer's Therapy to Be Presented at AAIC
Source: Streetwise Reports
July 11, 2018 (Investorideas.com Newswire) A poster outlining data from this company's lead candidate, which targets toxic oligomers identified as a potential cause of Alzheimer's disease, will be presented at the Alzheimer's Association International Conference (AAIC).
In a July 10 press release, ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) announced it would be presenting preclinical data regarding PMN310 at the AAIC, to be held in Chicago beginning on July 22.
The company, which is focused on "discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases," will present a poster titled "Humanized PMN310 shows enhanced therapeutic potential by binding toxic low molecular weight Aβ oligomers while avoiding ARIA-related binding to Aβ deposits in AD patient brains."
In the announcement, ProMIS chief development officer Johanne Kaplan stated that PMN310 "may provide greater therapeutic potency and safety compared to other Aβ-directed antibodies due to its selective targeting of soluble toxic oligomers and the consequently reduced risk of amyloid related imaging abnormalities, or ARIA, allowing for safe administration of higher doses of antibody."
According to the company, the processes leading to development of Alzheimer's disease may not stem from plaques, but rather from toxic amyloid beta (Aβ) oligomers. PMN310, according to ProMIS president and CEO Dr. Elliot Goldstein, "selectively target[s] and neutralize[s] toxic Aβ oligomers with no significant off-target binding to Aβ monomers or plaque."
In the release, Dr. Goldstein expressed the company's belief that "the particular, oligomer selective profile of PMN310 supports a potential best in class profile compared to [other] Aβ therapeutic antibodies currently showing promising results in clinical trials."
The company plans to begin clinical trials for PMN310 in the second half of 2019.
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire http://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.